A 58-year-old woman from Mumbai with a history of atrial fibrillation (AF) is prescribed warfarin for stroke prevention. She has been stable on warfarin 5 mg daily with an INR of 2.5 for the past 6 months. She now presents to the outpatient clinic with a 2-week history of epistaxis, gum bleeding, and easy bruising. Her INR is found to be 8.2. She denies any recent medication changes, dietary alterations, or alcohol use. On further questioning, she mentions starting a new herbal supplement (containing cranberry extract) 3 weeks ago for urinary tract infection prevention. What is the most likely mechanism of the elevated INR, and what is the immediate management?

Explanation

## Drug–Herbal Interaction: Cranberry and Warfarin ### Mechanism of Interaction **Key Point:** Cranberry (Vaccinium macrocarpon) contains proanthocyanidins and other polyphenolic compounds that potentiate warfarin's anticoagulant effect through multiple mechanisms: 1. **Inhibition of Vitamin K Recycling:** Cranberry polyphenols inhibit vitamin K epoxide reductase (VKOR) and vitamin K-dependent clotting factor synthesis (Factors II, VII, IX, X). 2. **CYP2C9 Inhibition:** Cranberry weakly inhibits CYP2C9, the primary enzyme responsible for warfarin metabolism, leading to increased warfarin levels. 3. **Platelet Function Impairment:** Cranberry has mild antiplatelet properties, adding to bleeding risk. **High-Yield:** This is a classic NEET PG high-yield drug–herbal interaction. Cranberry supplements are frequently used in India for UTI prevention and commonly cause warfarin interactions. ### Clinical Presentation **Clinical Pearl:** The patient's presentation with epistaxis, gum bleeding, and easy bruising indicates **over-anticoagulation** (INR 8.2 is supratherapeutic; target 2–3 for AF). The temporal relationship (INR elevation 3 weeks after cranberry initiation) confirms the herbal supplement as the culprit. ### Management Algorithm for Elevated INR Without Bleeding ```mermaid flowchart TD A[INR 8.2 on warfarin + cranberry]:::outcome --> B{Active bleeding?}:::decision B -->|Yes| C[Administer FFP + vitamin K 10 mg IV]:::action B -->|No| D[Assess bleeding risk]:::decision D -->|Minor bleeding signs: epistaxis, gum bleeding| E[Vitamin K 2.5-5 mg IV/PO]:::action D -->|No bleeding| F[Vitamin K 1-2.5 mg PO]:::action E --> G[Discontinue cranberry immediately]:::action F --> G G --> H[Hold warfarin until INR <4]:::action H --> I[Recheck INR in 24-48 hours]:::action I --> J{INR normalized?}:::decision J -->|Yes| K[Restart warfarin at lower dose]:::action J -->|No| L[Repeat vitamin K 1-2 mg]:::action K --> M[Educate on herbal supplement interactions]:::action ``` ### Why This Patient Requires Vitamin K (Not FFP Alone) | Management | Indication | Rationale | |------------|-----------|----------| | **Vitamin K 10 mg IV** | INR 8.2 + minor bleeding (epistaxis, gum bleeding) | Corrects INR within 12–24 hours; addresses underlying vitamin K deficiency caused by cranberry | | **FFP** | INR 8.2 + major bleeding (GI bleed, ICH) | Provides immediate clotting factors; used in emergencies; NOT indicated here | | **Vitamin K 2.5–5 mg PO** | INR 5–9 + no bleeding | Slower onset (24–48 hrs); suitable for outpatient management | | **Vitamin K 1–2 mg IV** | INR 4–6 + no bleeding | Minimal risk of over-correction; preferred to avoid warfarin resistance | **Warning:** High-dose vitamin K (10 mg) can cause warfarin resistance for 1–2 weeks, necessitating bridging with LMWH or UFH if immediate anticoagulation is critical. In this AF patient without acute thromboembolism, this is acceptable. ### Why NOT Protamine Sulfate? **Tip:** Protamine is the reversal agent for **heparin**, not warfarin. It has no role in warfarin over-anticoagulation. ### Why NOT FFP as First-Line? **Clinical Pearl:** FFP is reserved for **life-threatening bleeding** (INR >9 + major hemorrhage). This patient has minor bleeding signs and INR 8.2—vitamin K is the appropriate first-line agent. FFP is expensive, carries infection risk, and causes volume overload. ### Post-Correction Management 1. **Discontinue cranberry immediately** — educate patient on herbal–drug interactions. 2. **Hold warfarin** until INR <4 (typically 24–48 hours after vitamin K). 3. **Restart warfarin at a reduced dose** (e.g., 3–4 mg daily instead of 5 mg) once INR normalizes. 4. **Recheck INR** 3–5 days after warfarin restart to ensure therapeutic range (2–3 for AF). 5. **Counsel on herbal supplements** — many contain vitamin K (green tea, alfalfa) or potentiate warfarin (ginger, garlic, ginkgo). ### Differential Diagnosis of Elevated INR | Cause | Key Feature | Excluded Here | |-------|------------|---------------| | **Herbal interaction (cranberry)** | Temporal relationship; no other medication changes | **This is the diagnosis** | | **Dietary vitamin K deficiency** | Acute change in leafy green intake | Patient denies dietary changes | | **Liver disease** | Elevated bilirubin, AST, ALT; coagulopathy | No mention of hepatic dysfunction | | **Malabsorption** | Diarrhea, steatorrhea, weight loss | No GI symptoms reported | | **Drug interaction (NSAIDs, antibiotics)** | Recent medication initiation | Patient denies new medications | [cite:KD Tripathi 8e Ch 18; Harrison 21e Ch 295]